Stock Analysis

DBV Technologies Third Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.17 loss in 3Q 2023)

Advertisement

DBV Technologies (EPA:DBV) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$1.07m (down 55% from 3Q 2023).
  • Net loss: US$30.4m (loss widened by 82% from 3Q 2023).
  • US$0.32 loss per share (further deteriorated from US$0.17 loss in 3Q 2023).
earnings-and-revenue-growth
ENXTPA:DBV Earnings and Revenue Growth November 9th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

DBV Technologies Earnings Insights

Looking ahead, revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Biotechs industry in France.

Performance of the French Biotechs industry.

The company's shares are down 9.0% from a week ago.

Risk Analysis

You should learn about the 4 warning signs we've spotted with DBV Technologies (including 2 which can't be ignored).

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTPA:DBV

DBV Technologies

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

Adequate balance sheet with slight risk.

Advertisement

Updated Narratives

BE
Bejgal
MNSO logo
Bejgal on MINISO Group Holding ·

MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

Fair Value:US$26.6928.0% undervalued
44 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.5% undervalued
7 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
AU
AuCA
NLBR logo
AuCA on Nova Ljubljanska Banka d.d ·

Nova Ljubljanska Banka d.d will expect a 11.2% revenue boost driving future growth

Fair Value:€20916.3% undervalued
23 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3404.9% undervalued
134 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative
TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
83 users have followed this narrative
11 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$232.7923.6% undervalued
923 users have followed this narrative
5 users have commented on this narrative
22 users have liked this narrative